Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Eli Lilly

Main (gene editing) focus: Genetic disorders in the liver and nervous system

Company stage: Commercial

Diseases (gene editing): Liver diseases and diseases of the central nervous system

Genome editing tool: ADAR RNA editing, Arcus Meganuclease

Funding stage: Public (NASDAQ:LLY)

Location: Indianapolis, Indiana, USA



Gene editing partnerships: ProQR Therapeutics, Precision Biosciences

Eli Lilly is a big pharma company with several commercialised medicines in its portfolio. The company's involvment in the genome-editing space comes primarily through its collaboration with Precision Biosciences, where Eli Lilly gets access to the ARCUS meganuclease gene-editing technology to treat genetic diseases of muscle, CNS and liver. Another collaboration in this space is with ProQR Therapeutics, where Eli Lilly gains access to an ADAR-based RNA-editing technology.


HashtagEli Lilly

Company: Eli Lilly
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine